Moleculin reports positive Annamycin AML trial: median OS 15 mos for CR, 12 mos for 2L

Moleculin Biotech, Inc.

Phase 1b/2 MB-106 trial completed; median OS 15 months for complete remissions (n=8), 12 months for 2L efficacy evaluable (n=9).
Median OS for ITT population (1L-7L) was 9 months, exceeding typical 4-6 months for relapsed AML.
CR rate 36% ITT, 50% in 2L; 50% of CR subjects proceeded to bone marrow transplant; no cardiotoxicity.
Database lock expected Sep 2025; final clinical study report in Q1 2026; Phase 3 MIRACLE trial enrolling first 45 pts.
Authorized common shares increased from 100M to 500M effective Aug 21, 2025.

item 5.03item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.